{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:32:43Z","timestamp":1791570763184,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtct.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T12:01:41Z","timestamp":1747396901000},"page":"670.e1-670.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-0489","authenticated-orcid":false,"given":"Anmol","family":"Baranwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-0329","authenticated-orcid":false,"given":"Christopher","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabee","family":"Kassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-1654","authenticated-orcid":false,"given":"Gabriel","family":"Bartoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0497-4668","authenticated-orcid":false,"given":"Robert","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viswanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasyia","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urshila","family":"Durani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hefazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2025.05.006_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00129785-200404030-00005","article-title":"Diagnostic chimerism analysis after allogeneic stem cell transplantation","volume":"4","author":"Thiede","year":"2004","journal-title":"Am J PharmacoGenomics"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.006_bib0002","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.leu.2402311","article-title":"Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation","volume":"15","author":"Mattsson","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2025.05.006_bib0003","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.leu.2402550","article-title":"Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation","volume":"16","author":"P\u00e9rez-Sim\u00f3n","year":"2002","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.006_bib0004","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.leu.2403468","article-title":"Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival","volume":"18","author":"Lamba","year":"2004","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.006_bib0006","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2003-04-1170","article-title":"Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors","volume":"103","author":"Carvallo","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.006_bib0007","first-page":"1071","article-title":"Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan","volume":"86","author":"Niiya","year":"2001","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.006_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bmt.1703846","article-title":"Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning","volume":"31","author":"Valc\u00e1rcel","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.006_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence","volume":"50","author":"van Besien","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.006_bib0010","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bbmt.2008.07.013","article-title":"Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.05.006_bib0011","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1182\/blood-2022-156852","article-title":"Frequency and clinical significance of mixed T-cell chimerism following myeloablative busulfan and cyclophosphamide conditioning in HLA -matched donor transplants for myeloid malignancies: an analysis of 179 patients transplanted at a single center","volume":"140","author":"Bashey","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.006_bib0012","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2025.05.006_bib0013","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.006_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.05.006_bib0015","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"403","key":"10.1016\/j.jtct.2025.05.006_bib0016","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/01621459.1988.10478639","article-title":"Locally weighted regression: an approach to regression analysis by local fitting","volume":"83","author":"Cleveland","year":"1988","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2025.05.006_bib0017","unstructured":"Aragon TJ, Fay MP, Wollschlaeger D, Omidpanah A. epitools: epidemiology tools. R package version 0.5-10.1. 2020-03-22 09:46:12 UTC."},{"issue":"6","key":"10.1016\/j.jtct.2025.05.006_bib0018","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jrsm.1460","article-title":"Zero-cell corrections in random-effects meta-analyses","volume":"11","author":"Weber","year":"2020","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.006_bib0019","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"The Annals of Statistics"},{"issue":"446","key":"10.1016\/j.jtct.2025.05.006_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"282","key":"10.1016\/j.jtct.2025.05.006_bib0021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.006_bib0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2025.05.006_bib0023","article-title":"Utility of CD3+ T- lymphocyte chimerism following myeloablative allogeneic hematopoietic stem cell transplant (HSCT): a single center experience","volume":"33","author":"Akpoguma","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.006_bib0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.006_bib0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41409-021-01518-0","article-title":"Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin","volume":"57","author":"Yeh","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.006_bib0026","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/sj.bmt.1704985","article-title":"Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning","volume":"35","author":"Yoshihara","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.006_bib0027","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41409-022-01779-3","article-title":"Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant","volume":"57","author":"Baranwal","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.006_bib0028","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3324\/haematol.2018.199398","article-title":"Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms","volume":"104","author":"Monaco","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.006_bib0029","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.006_bib0030","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.006_bib0031","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725011674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725011674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:31:57Z","timestamp":1756211517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725011674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666636725011674"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}